Navigation Links
Anxiety Disorders & Depression Treatment Market Worth $18.3 Billion by 2025: Grand View Research, Inc.
Date:1/23/2017

SAN FRANCISCO, January 23, 2017 /PRNewswire/ --

The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in the recent years.

Continue Reading
Grand View Research Logo
Grand View Research Logo

     (Logo: http://photos.prnewswire.com/prnh/20150105/723757)

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

Browse full research report with TOC on "Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/anxiety-disorders-and-depression-treatment-market

Further key findings from the study suggest: 

  • Presently, the antidepressant drugs segment holds the largest revenue share. However, due to the rising occurrence of adverse events associated with these therapeutics, this segment's growth is expected to wane
  • Patent expiration of branded medicines and introduction of generic biosimilars, which are cost effective, are responsible for the shrinking market of antidepressants
  • On the other hand, introduction of new medicines, such as Duloxetine, Fetzima, and Brintellix, are predicted to fuel the demand for therapeutics in the coming years
  • Furthermore, the personalized therapies and devices segment is expected to register the fastest growth owing to its growing adoption by healthcare professionals as they exert fewer side effects as compared to drugs
  • Cognitive behavioral therapy held the majority share in 2015 and is expected to register substantial growth in the coming years owing to the shifting preference of healthcare professionals toward this segment
  • Transcranial Magnetic Stimulation (TMS) is predicted to witness lucrative growth due to the introduction of technologically advanced devices such as MagVita TMS Therapy System by MagVenture in July 2015 and Brainsway Deep TMS in January 2013
  • North American regional segment for anxiety disorders and depression treatment reached a saturation level owing to the availability of several medicines and the high prevalence of depressive disorders in this region
  • Pfizer, Inc.; Eli Lilly and Company;GlaxoSmithKline plc; AstraZeneca; and H. Lundbeck A/S captured a sizable share in 2015 and accounted for more than 60% of the antidepressant drugs vertical
  • The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period

Browse related reports by Grand View Research: 

Grand View Research has segmented the anxiety disorders and depression treatment market by product, indication, and region:

  • Anxiety Disorder and Depression Treatment Product Outlook (Revenue, USD Million, 2014 - 2025)
    • Antidepressant drugs
      • SSRIs
      • SNRIs
      • TCAs
      • MAOIs
      • Atypical Antipsychotics
      • Benzodiazepines
      • Anticonvulsants
      • Beta-Blockers
      • Others
    • Therapy & Devices
      • Fischer Wallace Stimulator
      • TMS
      • DBS
      • VNS
      • ECT
      • CBT
      • Others
  • Anxiety Disorder and Depression Treatment Indication Outlook (Revenue, USD Million, 2014 - 2025)
    • MDD
    • OCD
    • Phobias
    • Others
  • Anxiety Disorder and Depression Treatment Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
      • U.S
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • The Middle East and Africa
      • South Africa

Read Our Blog - Anxiety Disorders and Depression Treatment Market: Expected To Witness Steady Growth

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com


Web: http://www.grandviewresearch.com 


'/>"/>
SOURCE Grand View Research, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Breakthrough in Brain Surgery: Asleep DBS Can Relieve Fear and Anxiety Surrounding Surgery
2. Anxiety Disorders Therapeutic Pipeline Review H1 2015
3. Bionomics Initiates Phase II Clinical Trial of BNC210 for Treatment of Anxiety
4. Now, a Whole New View About Managing Anxiety - Special Sunglasses
5. PA Wolf Administration Officials Release Safe Prescribing Guidelines for Anxiety and Insomnia Medications to Help Curb Overdose Risk
6. Alternatives Available Nationwide to Addictive Benzodiazepines for Anxiety
7. Breakthrough Method for Lipid Analysis in Fecal Material Developed; New Understanding of Diseases/Disorders Related to Gut Function Possible
8. Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
9. Research-based Pharmaceutical Industry Launches Do You Mind? Campaign to Fight Mental and Neurological Disorders
10. Boston Scientific Announces Collaboration with Pelvic Floor Disorders Network to Study Treatment Strategies for Uterine Prolapse
11. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
Breaking Medicine Technology:
(Date:5/26/2017)... Plano, Texas (PRWEB) , ... May 26, 2017 , ... ... Cord Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita ... , “We are pleased to be the first in Arkansas to introduce the ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: ... FAMILY-Our Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... used to say, he is "panther quick and leather tough." His love for others ...
(Date:5/26/2017)... ... ... Water damage to the flooring of several classrooms at The Fort Lee Elementary ... number of critical issues to address before students could return to classes. , First, ... no disruption to class schedules. Second, the project had to comply with New Jersey ...
Breaking Medicine News(10 mins):